Your browser is no longer supported. Please, upgrade your browser.
Settings
REPL Replimune Group, Inc. daily Stock Chart
REPL [NASD]
Replimune Group, Inc.
Index- P/E- EPS (ttm)-1.66 Insider Own14.00% Shs Outstand39.86M Perf Week10.30%
Market Cap1.75B Forward P/E- EPS next Y-2.18 Insider Trans-3.92% Shs Float35.71M Perf Month118.99%
Income-60.60M PEG- EPS next Q-0.44 Inst Own85.10% Short Float2.61% Perf Quarter138.27%
Sales- P/S- EPS this Y-15.60% Inst Trans-2.50% Short Ratio1.74 Perf Half Y263.34%
Book/sh6.97 P/B6.48 EPS next Y-11.00% ROA-25.10% Target Price38.63 Perf Year198.55%
Cash/sh6.77 P/C6.68 EPS next 5Y- ROE-31.10% 52W Range8.58 - 47.96 Perf YTD214.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.75% Beta-
Dividend %- Quick Ratio22.50 Sales past 5Y- Gross Margin- 52W Low426.81% ATR3.55
Employees122 Current Ratio22.50 Sales Q/Q- Oper. Margin- RSI (14)82.96 Volatility8.61% 11.71%
OptionableNo Debt/Eq0.13 EPS Q/Q-46.10% Profit Margin- Rel Volume2.62 Prev Close43.39
ShortableYes LT Debt/Eq0.12 Earnings- Payout- Avg Volume535.63K Price45.20
Recom1.90 SMA2050.96% SMA5071.66% SMA200130.03% Volume1,400,835 Change4.17%
Oct-15-20Upgrade H.C. Wainwright Neutral → Buy $25 → $54
Jul-01-20Downgrade H.C. Wainwright Buy → Neutral $25
May-05-20Initiated Barclays Overweight $21
Sep-04-19Initiated ROTH Capital Buy $20
Jul-23-19Initiated Chardan Capital Markets Buy $28
Jul-12-19Upgrade JP Morgan Neutral → Overweight $27 → $26
Jul-08-19Initiated H.C. Wainwright Buy $26
Apr-25-19Initiated Wedbush Outperform $24
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Aug-14-18Initiated Leerink Partners Outperform $25
Aug-14-18Initiated JP Morgan Overweight $26
Oct-22-20 01:09AM  
Oct-20-20 04:02PM  
04:01PM  
Oct-19-20 04:01PM  
Oct-15-20 11:33AM  
09:51AM  
Oct-14-20 12:29PM  
Aug-07-20 07:00AM  
Aug-04-20 07:00AM  
Jul-22-20 07:00AM  
Jun-22-20 02:27PM  
Jun-17-20 08:00AM  
Jun-11-20 08:47AM  
Jun-08-20 11:21PM  
04:16PM  
Jun-03-20 07:15AM  
07:00AM  
Apr-30-20 06:00AM  
Apr-02-20 07:00AM  
Feb-13-20 07:00AM  
Feb-06-20 08:00AM  
Jan-13-20 07:00AM  
Jan-09-20 07:00AM  
Jan-07-20 08:00AM  
Dec-23-19 02:56PM  
Dec-09-19 08:00AM  
Nov-26-19 08:00AM  
Nov-22-19 12:13PM  
Nov-14-19 06:22AM  
Nov-12-19 04:06PM  
Nov-11-19 08:00AM  
Nov-08-19 07:30AM  
Oct-31-19 04:00PM  
02:19PM  
Oct-24-19 08:00AM  
Oct-15-19 07:00AM  
Oct-02-19 08:00AM  
Oct-01-19 08:00AM  
Sep-13-19 04:39AM  
Aug-14-19 08:00AM  
Aug-06-19 08:00AM  
Jul-19-19 09:16AM  
Jun-28-19 08:00AM  
Jun-01-19 09:00AM  
May-30-19 08:00AM  
May-16-19 07:00AM  
Apr-25-19 02:23PM  
Apr-01-19 07:00AM  
Feb-14-19 08:00AM  
Feb-07-19 08:00AM  
Jan-04-19 12:33PM  
Jan-03-19 08:00AM  
Dec-20-18 08:00AM  
Dec-08-18 06:19PM  
Dec-05-18 08:00AM  
Nov-14-18 08:38AM  
08:00AM  
Sep-26-18 08:00AM  
Sep-06-18 04:01PM  
Aug-30-18 08:00AM  
Aug-14-18 02:49PM  
Jul-24-18 07:44AM  
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Esposito PamelaChief Business OfficerOct 14Option Exercise1.0116,00016,160128,700Oct 16 06:05 PM
Esposito PamelaChief Business OfficerOct 14Sale32.9016,000526,410112,700Oct 16 06:05 PM
Love ColinChief Operating OfficerSep 15Sale23.9715,000359,4871,021,524Sep 17 04:25 PM
Esposito PamelaChief Business OfficerAug 31Option Exercise1.015,0005,050117,700Sep 01 05:13 PM
Esposito PamelaChief Business OfficerAug 31Sale27.055,000135,250112,700Sep 01 05:13 PM
Love ColinChief Operating OfficerAug 17Sale23.4415,000351,5551,036,524Aug 18 05:15 PM
Coffin RobertPresident & Chief R&D OfficerJul 09Sale22.13169,7503,757,2952,024,118Jul 10 09:00 PM
Coffin RobertPres & Chief Res & Dev OfficerFeb 20Sale17.0424,250413,2202,193,868Feb 24 04:02 PM
Coffin RobertPres & Chief Res & Dev OfficerFeb 12Sale17.0448,500826,1982,218,118Feb 14 04:00 PM
Esposito PamelaChief Business OfficerDec 20Option Exercise1.7525,70044,975112,700Dec 23 04:32 PM
Kaufman HowardChief Medical OfficerNov 26Option Exercise3.3058,067191,62158,067Dec 19 04:02 PM
Rhodes Jason PDirectorNov 18Buy13.611,100,00014,971,0001,100,000Nov 20 05:50 PM
Omega Fund IV, L.P.10% OwnerNov 18Buy13.61220,0002,994,2005,328,939Nov 20 12:36 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.